There are assessment reports for different medicinal products with infliximab. The latest information is for Zessly (infliximab) 22 March 2018, EMA/223369/2018.
"The active substance is a natural substance, a protein and therefore unlikely to pose a significant risk to the environment. This is in accordance with the CHMP Guideline on the environmental risk assessment of medicinal products for human use (EMEA/CHMP/SWP/4447/00 corr 2)."
There is environmental information about infliximab from Pfizer (Inflectra), MSD (Remicade) och Orion Pharma (Remsima), downloaded 2019-09-03.
The use of amino acids, proteins and peptides is not expected to have any environmental impact.
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00) vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
Author: Health and Medical Care Administration, Region Stockholm